Companion Diagnostics Market Overview
The Companion Diagnostics Market is expanding as precision medicine and targeted therapies become increasingly important in modern healthcare. Growing adoption of molecular testing, increasing development of oncology drugs linked with companion diagnostics, advances in next-generation sequencing, liquid biopsy commercialization, and rising investments in genomic infrastructure are supporting market growth.
According to the Market Research Future report updated August 6, 2026, the global Companion Diagnostics Market stood at USD 9.32 Billion in 2025 and is projected to grow from USD 10.36 Billion in 2026 to USD 26.83 Billion by 2035, registering a CAGR of 11.15% during 2026–2035. North America led the market with approximately 43.15% share in 2025, while Asia-Pacific is the fastest-growing region with a projected CAGR of 13.45%. PCR retained the largest technology share at 23.50%, Lung Cancer accounted for approximately 20.40% of the market, and Assays and Kits dominated product-type revenues with 70.80% share.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.marketresearchfuture.com/sample_request/3077
Key players driving innovation and competitiveness in the Companion Diagnostics Market include:
Roche Diagnostics
Abbott Laboratories
Agilent Technologies
Thermo Fisher Scientific
QIAGEN
Illumina
Guardant Health
Myriad Genetics
bioMérieux
Exact Sciences
The market is being shaped by increasing regulatory emphasis on companion diagnostic co-development, growing adoption of precision oncology, expansion of molecular testing, declining sequencing costs, and improvements in reimbursement frameworks. Next-generation sequencing is enabling comprehensive multi-gene testing, while liquid biopsy is creating opportunities for non-invasive treatment selection and monitoring. AI-driven diagnostic interpretation and emerging multi-omic platforms are also expected to influence the future of companion diagnostics.
The Companion Diagnostics Market can be segmented by Test Type into HER2 Testing, PD-1 Testing, EGFR Mutation Testing, ALK Rearrangement Testing, and Others. By Product & Services, it includes Assays, Reagents & Kits, Instruments/Systems, and Software & Services. By Technology, it covers Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), and Others. By Indication, it includes Cancer, Neurological Disorders, Cardiovascular Disorders, and Infectious Diseases. By End User, it covers Biopharmaceutical and Biotechnology Companies, CROs and CDMOs, and Others.
The growing need for personalized treatment selection is creating opportunities for diagnostic manufacturers, pharmaceutical companies, biotechnology firms, CROs, CDMOs, hospitals, reference laboratories, and genomic technology providers. Liquid biopsy, AI-powered interpretation, multi-cancer testing, next-generation sequencing panels, pharmacogenomic applications, and real-world evidence platforms can support market differentiation and future growth.
Recent Developments and Market Trends:
PCR remains the largest technology segment with 23.50% share, supported by its established role in single-gene mutation testing such as EGFR and BRAF.
Next-Generation Sequencing is the fastest-expanding technology segment, supported by multi-gene panel approvals, declining sequencing costs, and increasing demand for comprehensive genomic profiling.
Lung Cancer represents the largest indication with approximately 20.40% share, driven by the increasing use of molecular testing for actionable biomarkers.
Assays and Kits dominate product-type revenues with 70.80% share because of their direct connection to drug launches and label expansions.
Liquid Biopsy is emerging as a high-growth sample category, supported by non-invasive testing, faster turnaround times, and the ability to monitor treatment response.
Software and Services are expanding rapidly as AI-assisted interpretation platforms help clinicians analyze increasingly complex genomic and molecular datasets.
Asia-Pacific is the fastest-growing regional market at a projected 13.45% CAGR, supported by genomic infrastructure investments in China and India.
AI-driven diagnostic interpretation, multi-omic testing, pharmacogenomics, and emerging-market genomic infrastructure are creating new opportunities beyond traditional oncology-focused companion diagnostics.
Reasons to Buy the Report:
Provides comprehensive insights into the Companion Diagnostics Market dynamics, trends, opportunities, and growth potential.
Helps identify opportunities across HER2, PD-1, EGFR, ALK, and other companion diagnostic testing applications.
Offers detailed segmentation analysis across test type, product and services, technology, indication, end user, and geographic markets.
Includes competitive intelligence covering leading diagnostic, biotechnology, pharmaceutical, and genomic technology companies.
Supports informed decisions using market forecasts, precision oncology trends, regulatory developments, NGS adoption, liquid biopsy commercialization, AI integration, and regional opportunities.
Future Outlook:
The future of the Companion Diagnostics Market will be shaped by precision medicine, regulatory mandates for CDx co-development, next-generation sequencing, liquid biopsy, AI-powered diagnostic interpretation, and expanding genomic infrastructure. PCR should remain an important technology segment, while NGS is positioned for the fastest growth. Lung Cancer should continue to represent the largest indication, while Melanoma and other emerging indications are expected to expand rapidly. Assays and Kits should remain the leading product category, while Software and Services are positioned for strong growth as AI becomes increasingly integrated into diagnostic workflows. Tissue Biopsy should remain widely used, while Liquid Biopsy is expected to gain substantial adoption. North America should retain market leadership, while Asia-Pacific should remain the fastest-growing region. Market Research Future projects the market to reach USD 26.83 Billion by 2035 at a CAGR of 11.15%.
➤➤Explore Our Latest Related Reports:
